Summary & Overview
HCPCS Level II C9442: Belinostat Injection, 10 mg
HCPCS Level II code C9442 denotes a 10 mg injection of belinostat, an intravenous antineoplastic agent used in oncology care. Nationally, accurate coding for specialty oncology drugs matters for claims processing, reimbursement transparency, and pharmacy management. This code identifies the drug product and potency rather than the administration procedure, supporting drug-specific reporting and price tracking.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of coding context, payer coverage considerations, and typical sites of service. The publication summarizes benchmark pricing and utilization concepts for injectable oncology drugs, highlights relevant billing and documentation touchpoints, and outlines clinical context for belinostat use.
The content provides a national perspective on the role of HCPCS Level II coding for oncology injectables, what to expect in payer interactions, and how this code is used in service line reporting. Data not supplied in the input is identified as unavailable where applicable.
Billing Code Overview
HCPCS Level II code C9442 represents the drug formulation belinostat, billed as an injection in 10 mg units. This code is used to report administration of the medication itself rather than the administration procedure.
Service type: Drug administration — injectable antineoplastic agent
Typical site of service: Hospital outpatient infusion center or clinic
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with relapsed or refractory peripheral T-cell lymphoma or another hematologic malignancy for which belinostat is indicated. The patient presents to an outpatient infusion center or hospital outpatient clinic for intravenous chemotherapy. The oncology nurse verifies orders, performs pre-infusion assessment (vital signs, lab review including liver function tests and CBC), obtains venous access (peripheral IV or implanted port), and prepares belinostat dosing based on body surface area per oncology order. The drug is administered as an intravenous infusion, with monitoring for infusion reactions, hematologic toxicity, and hepatic adverse effects. Post-infusion nursing assessment documents tolerance, and the patient receives discharge instructions including symptom monitoring and follow-up oncology appointments. Typical site of service: outpatient infusion center or hospital outpatient department. Service type: chemotherapy drug administration (parenteral oncologic agent).
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
25 | Significant, separately identifiable evaluation and management service on the same day | Use when a distinct E/M visit is provided on the same day as the infusion and documented separately. |
59 | Distinct procedural service | Use to indicate a distinct service when multiple procedures or services might be bundled.